Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10676MR)

This product GTTS-WQ10676MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10676MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14713MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SEG101
GTTS-WQ5119MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ7927MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ962MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-323
GTTS-WQ6602MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ6003MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO 095
GTTS-WQ15431MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TSR-033
GTTS-WQ1168MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABP 501
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW